Home Biosimilar Antibodies Cytoskeletal Signaling Integrin Erlizumab (Anti-Integrin b2 / ITGB2 / CD18)
For research use only. Not for use in humans.

Erlizumab (Anti-Integrin b2 / ITGB2 / CD18)

Synonyms: ITGB2， CD18

Erlizumab (anti-Integrin b2 / ITGB2 / CD18) is a humanized monoclonal antibody targeted against Integrin beta-2 and used as a therapy for hemorrhagic shock. MW: 146.66 kD.

Erlizumab (Anti-Integrin b2 / ITGB2 / CD18)

Quality Control

Batch: A271201 Purity: 99% Protein concentration: 5.857mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation Integrin ILK Others
Cilengitide trifluoroacetate 71
A-205804 7
GLPG0187 1
GSK-3008348 HCl 0
Bexotegrast (PLN-74809) 1
Cilengitide (EMD 121974) 37
OSU-T315 1
TR-14035 0
Cyclo(RGDyK) TFA 15
SB273005 27
RGD peptide (Arg-Gly-Asp) 27
ILK-IN-3 1
RGD peptide (GRGDNP) 5 caspase-3
ATN-161 22
Cyclo(-RGDfK) TFA 14
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Erlizumab (anti-Integrin b2 / ITGB2 / CD18) is a humanized monoclonal antibody targeted against Integrin beta-2 and used as a therapy for hemorrhagic shock. MW: 146.66 kD.
References

Product Details

CAS No. 211323-03-4
Molecular Weight 146.66
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03812263 COMPLETED Leukocyte Adhesion Defect - Type I Rocket Pharmaceuticals Inc. 2019-08-30 PHASE1; PHASE2
NCT03825783 WITHDRAWN Leukocyte Adhesion Defect - Type I Rocket Pharmaceuticals Inc. 2019-04-15 PHASE1
NCT02247375 COMPLETED Drug: Low dose of BIIL 284 BS tablets|Drug: High dose of BII Arthritis, Rheumatoid Boehringer Ingelheim 2000-01 PHASE1

(data from https://clinicaltrials.gov, updated on 2023-11-15)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.